Literature DB >> 12950143

Dual reporter transgene driven by 2.3Col1a1 promoter is active in differentiated osteoblasts.

Inga Marijanović1, Xi Jiang, Mark S Kronenberg, Mary Louise Stover, Ivana Erceg, Alexander C Lichtler, David W Rowe.   

Abstract

AIM: As quantitative and spatial analyses of promoter reporter constructs are not easily performed in intact bone, we designed a reporter gene specific to bone, which could be analyzed both visually and quantitatively by using chloramphenicol acetyltransferase (CAT) and a cyan version of green fluorescent protein (GFPcyan), driven by a 2.3-kb fragment of the rat collagen promoter (Col2.3).
METHODS: The construct Col2.3CATiresGFPcyan was used for generating transgenic mice. Quantitative measurement of promoter activity was performed by CAT analysis of different tissues derived from transgenic animals; localization was performed by visualized GFP in frozen bone sections. To assess transgene expression during in vitro differentiation, marrow stromal cell and neonatal calvarial osteoblast cultures were analyzed for CAT and GFP activity.
RESULTS: In mice, CAT activity was detected in the calvaria, long bone, teeth, and tendon, whereas histology showed that GFP expression was limited to osteoblasts and osteocytes. In cell culture, increased activity of CAT correlated with increased differentiation, and GFP activity was restricted to mineralized nodules.
CONCLUSION: The concept of a dual reporter allows a simultaneous visual and quantitative analysis of transgene activity in bone.

Entities:  

Keywords:  NASA Discipline Cell Biology; Non-NASA Center

Mesh:

Substances:

Year:  2003        PMID: 12950143

Source DB:  PubMed          Journal:  Croat Med J        ISSN: 0353-9504            Impact factor:   1.351


  8 in total

1.  Pregnancy-associated plasma protein-A increases osteoblast proliferation in vitro and bone formation in vivo.

Authors:  Xuezhong Qin; Jon E Wergedal; Mark Rehage; Kiet Tran; Jacqueline Newton; Paggie Lam; David J Baylink; Subburaman Mohan
Journal:  Endocrinology       Date:  2006-08-31       Impact factor: 4.736

2.  CCAAT/Enhancer-binding protein homologous protein (CHOP) decreases bone formation and causes osteopenia.

Authors:  Renata C Pereira; Lisa E Stadmeyer; Deanna L Smith; Sheila Rydziel; Ernesto Canalis
Journal:  Bone       Date:  2006-11-07       Impact factor: 4.398

3.  Transgenic mice expressing a ligand-inducible cre recombinase in osteoblasts and odontoblasts: a new tool to examine physiology and disease of postnatal bone and tooth.

Authors:  Jung-Eun Kim; Kazuhisa Nakashima; Benoit de Crombrugghe
Journal:  Am J Pathol       Date:  2004-12       Impact factor: 4.307

4.  Multimodal evaluation of tissue-engineered cartilage.

Authors:  Joseph M Mansour; Jean F Welter
Journal:  J Med Biol Eng       Date:  2013-02-01       Impact factor: 1.553

5.  Targeting of androgen receptor in bone reveals a lack of androgen anabolic action and inhibition of osteogenesis: a model for compartment-specific androgen action in the skeleton.

Authors:  Kristine M Wiren; Anthony A Semirale; Xiao-Wei Zhang; Adrian Woo; Steven M Tommasini; Christopher Price; Mitchell B Schaffler; Karl J Jepsen
Journal:  Bone       Date:  2008-05-16       Impact factor: 4.398

6.  Positive regulation of adult bone formation by osteoblast-specific transcription factor osterix.

Authors:  Wook-Young Baek; Min-A Lee; Ji Won Jung; Shin-Yoon Kim; Haruhiko Akiyama; Benoit de Crombrugghe; Jung-Eun Kim
Journal:  J Bone Miner Res       Date:  2009-06       Impact factor: 6.741

7.  Bone-specific overexpression of NPY modulates osteogenesis.

Authors:  I Matic; B G Matthews; T Kizivat; J C Igwe; I Marijanovic; S T Ruohonen; E Savontaus; D J Adams; I Kalajzic
Journal:  J Musculoskelet Neuronal Interact       Date:  2012-12       Impact factor: 2.041

8.  Targeting Adeno-Associated Virus Vectors for Local Delivery to Fractures and Systemic Delivery to the Skeleton.

Authors:  Lucinda R Lee; Lauren Peacock; Leszek Lisowski; David G Little; Craig F Munns; Aaron Schindeler
Journal:  Mol Ther Methods Clin Dev       Date:  2019-09-05       Impact factor: 6.698

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.